Invention:
This invention is for a genetic polymorphism test for assessing the risk of postpartum hemorrhage (PPH) and consequently the need for pharmacological oxytocin. This novel test uses a blood or saliva sample to identify key epigenetic variants linked to oxytocin receptor gene function, ultimately allowing for assessment of responsiveness to the medication.
Background:
Postpartum hemorrhage (PPH) is the leading cause of maternal mortality. It is responsible for 25% of deaths annually and affecting around 14 million women each year, particularly in low-income countries. For decades, a lack of research and development of methods and technology to combat PPH persists, with prediction tools being especially scarce. Traditional methods of PPH treatment and diagnosis rely on blood tests, ultrasounds, and specific genetic predispositions that are not completely effective means of prediction. This new method of testing focuses on identification of specific markers of DNA methylation sites for determination of responsiveness to life saving medication administrated during PPH.
Applications:
- A diagnostic test based on epigenetic factors for determination of oxytocin responsiveness and PPH risk
Advantages:
- Allows for knowledge in advance of risk of PPH
- Uses specific epigenetic factors for more accurate diagnosis
- Can be taken seamlessly by blood or saliva test
- Distinguishes between different levels pf oxytocin responsiveness
